TASK DEFINITION: Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
PROBLEM: Thirteen years ago, the Advisory Committee on Immunization Practices recommended hepatitis A shots for all U.S. children at age 1. On Thursday, the panel said the shots should be given to older children who weren’t vaccinated earlier, including 14- to 18-year-olds who turned 1 before the recommendation was made. The panel also recommended the shots for every person with HIV. About 1.1 million Americans are estimated to have HIV, the virus that causes AIDS. People with HIV tend to develop more severe hepatitis A illnesses. U.S. hepatitis A infections and deaths have risen in the last two years, spurred by outbreaks among the homeless and drug users.

SOLUTION: Health panel: Millions of US kids should get hepatitis shot.

PROBLEM: One new study found that heart attack survivors benefited from a medicine long used to treat gout. Several experimental drugs also showed early promise for interfering with heart-harmful genes without modifying the genes themselves — in one case, with treatment just twice a year. The research was featured at an American Heart Association conference ending Monday in Philadelphia. “There’s a lot of excitement” about the new gene-targeting medicines, especially because they seem to last so long, said Dr. Karol Watson, of the University of California, Los Angeles. Scientists have been exploring gene therapy — altering DNA — to attack the root cause of many diseases. The new drugs essentially accomplish the same thing without tampering with genes, said the University of Pennsylvania’s Dr. Daniel Rader, who has consulted for some makers of these drugs. The medicines work by silencing or blocking messages that genes give to cells to make proteins that can do harm, such as allowing cholesterol to accumulate. The first few of these “RNA-interference” drugs recently were approved for other conditions, and research is also targeting heart disease. Farthest along is inclisiran, tested in 1,561 people with heart disease from clogged arteries who still had high LDL, the bad form of cholesterol, despite taking standard drugs. They were given a shot of inclisiran or a dummy drug when they joined the study, three months later and then every six months. The drug lowered LDL by 56% without serious side effects. More testing will show whether it also lowers heart attacks and other problems, not just cholesterol. Inclisiran’s maker, The Medicines Company, plans to seek federal approval for it later this year. Two other RNA interference drugs aim at a different target — triglycerides, another fat in the blood that’s elevated in one quarter of Americans. Treatments include very low-fat diets, weight loss, fish oil and drugs, but doctors say more and better therapies are needed. Each RNA interference drug was tested at various doses in 40 people. A single shot lowered triglycerides by 30% to 67%, and the benefit lasted for at least four months. The studies were just intended to show safety; Arrowhead Pharmaceuticals is developing both drugs. Other research found new benefits from older drugs. AstraZeneca’s Farxiga, originally developed to treat diabetes, also lowered the risk of heart problems in heart failure patients who did not have diabetes. Among 2,605 of such patients treated for 18 months, about 9% of those on Farxiga had worsening heart failure or heart-related death versus nearly 13% of those not given the drug. That worked out to a 27% lower risk, without extra serious side effects. Surprising benefits also were seen in a Canadian study of the decades-old gout drug. The anti-inflammatory drug colchicine — sold as Colcrys, Mitigare and in generic form — was tested in 4,745 people who recently had a heart attack. After about two years, colchicine users had a 23% lower risk of suffering a new heart attack, heart-related death, stroke, cardiac arrest or urgent need for an artery-opening procedure compared with a group given dummy pills. The benefit came mostly from preventing strokes and artery-opening procedures, and some heart doctors would rather have seen more difference in heart attacks and deaths. Colchicine is being tested in several other studies, and more evidence is needed before using it routinely to lower heart risks, Dr. L. Kristin Newby of Duke University wrote in a commentary published with the study in the New England Journal of Medicine. Dr. Donald Lloyd-Jones, a Northwestern University cardiologist and program chief for the heart conference, was more supportive. “When you have a safe drug that’s easily available, it’s going to be hard to hold this one back,” he said. ___ Marilynn Marchione can be followed on Twitter at http://twitter.com/MMarchioneAP ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

SOLUTION: New, old drugs may offer fresh ways to fight heart disease.

PROBLEM: But the number of people in intensive care units fell to 6,730 from 6,821 over 24 hours - declining for a sixth consecutive day, suggesting the national lockdown put in place on March 17 is having some success in containing the disease. On Monday, President Emmanuel Macron announced a second extension of this lockdown until May 11, saying that progress had been made but also that the country had not been sufficiently prepared early on to surmount the challenges posed by the outbreak of the new coronavirus. Jerome Salomon, head of the public health authority, told a news conference that the number of COVID-19 deaths in French hospitals and nursing homes had risen by 5% in a day to a cumulative total of 15,729, versus 4% on Monday and Sunday. He added that the total number of confirmed infections had climbed by 5.3% to 103,573, compared to a rate of increase of 2.8% on Monday and of 1.7% on Sunday. There were also 26,680 suspected coronavirus cases in nursing homes, taking the total to more than 130,000 confirmed and possible cases, the fifth highest in the world. According to various running simulations, Salomon said that, depending on calculations for different regions, 5%-10% of the French population had probably contracted the disease.

SOLUTION:
France's rate of coronavirus infections, deaths accelerating again.